Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant erdafitinib alone or with cetrelimab in cisplatin-ineligible FGFR-altered muscle-invasive bladder cancer
2022-002586-15Phase 2Active
- Sponsor
- SOGUG
- Start
- Nov 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of erdafitinib and cetrelimab in bladder cancer (2 arms), sponsored by SOGUG. Primary endpoint: pT0N0 rate. Started Nov 2022; status: active.
02
Drugs
erdafitinibcetrelimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2022-002586-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002586-15.